Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Abiraterone
Drug ID BADD_D00014
Description Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.
Indications and Usage Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.
Marketing Status approved
ATC Code L02BX03
DrugBank ID DB05812
KEGG ID Not Available
MeSH ID C089740
PubChem ID 132971
TTD Drug ID D02STN
NDC Product Code 42291-024; 42291-073; 69238-1754; 60219-1754; 60687-455; 17337-0082; 54893-0070; 30007-838; 69238-1165; 60219-1165
UNII G819A456D0
Synonyms abiraterone | 17-(3-pyridyl)androsta-5,16-dien-3beta-ol | CB-7598 | CB 7598 | CB7598
Chemical Information
Molecular Formula C24H31NO
CAS Registry Number 154229-19-3
SMILES CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gastric ulcer haemorrhage24.07.02.003; 07.04.03.0050.000901%Not Available
Gastrointestinal carcinoma16.13.04.001; 07.21.03.0010.000334%Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.0050.002269%
Generalised oedema14.05.06.007; 08.01.07.0040.002469%
Glucose tolerance impaired14.06.02.001; 05.06.02.0010.000834%
Groin pain15.03.02.0040.001301%Not Available
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.0060.004938%
Haemolytic uraemic syndrome20.01.03.011; 01.06.02.0010.000334%
Haemorrhage subcutaneous24.07.06.010; 23.06.07.0020.001835%Not Available
Hair growth abnormal23.02.06.0060.001702%Not Available
Hepatic cirrhosis09.01.04.001--Not Available
Hepatic function abnormal09.01.02.0010.017018%Not Available
Hepatitis09.01.07.004--Not Available
Hepatitis acute09.01.07.0050.000501%Not Available
Hepatitis fulminant11.07.01.003; 09.01.07.0070.000334%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.0090.004872%Not Available
Hernia08.01.04.0010.001401%Not Available
Hydronephrosis20.01.05.0010.000667%Not Available
Hyperchlorhydria07.11.03.0010.001135%Not Available
Hypercholesterolaemia14.08.01.001--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.0020.007308%
Hyperkalaemia14.05.03.0010.005239%
Hypernatraemia14.05.04.0010.001068%
Hypersomnia19.02.05.001; 17.15.01.001--
Hypertension24.08.02.0010.031132%
Hypertriglyceridaemia14.08.02.001--
Hypervolaemia02.05.04.019; 14.05.06.0030.001401%Not Available
Hypoalbuminaemia14.10.01.002; 09.01.02.0030.000834%
Hypocalcaemia14.04.01.0040.001735%
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 12 Pages